07/19/04

IFW

PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/702,681
Filing Date	November 5, 2003
First Named Inventor	Deborah A. RATHJEN
Art Unit	1644
Examiner Name	C. Chan
Total Number of Pages in This Submission: 15	Attorney Docket Number: 273402602309

ENCLOSURES (*Check all that apply*)

- [ ] Fee Transmittal Form
  - [ ] Fee Attached
- [ ] Amendment/Reply
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [x] Information Disclosure Statement, Supplemental - 3 pages
- [ ] Certified Copy of Priority Document(s)
- [ ] Response to Missing Parts/ Incomplete Application
  - [ ] Response to Missing Parts under 37 CFR 1.52 or 1.53
- [ ] Drawing(s)
- [ ] Licensing-related Papers
- [ ] Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation Change of Correspondence Address
- [ ] Terminal Disclaimer
- [ ] Request for Refund
- [ ] CD, Number of CD(s) _____
- [ ] After Allowance Communication to Group
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to Group **(Appeal Notice, Brief, Reply Brief)**
- [ ] Proprietary Information
- [ ] Status Letter
- [x] Other Enclosure(s) (please identify below):

  Form PTO-1449 - 11 pages

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MORRISON & FOERSTER LLP (Customer No. 25226) Kimberly A. Bolin - 44,546
Signature	
Date	July 15, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335370849, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7/15/04 Signature: _____ (Tia B. Zimmerman)

PATENT
Docket No. 273402602309
Client Reference: 501927

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335370849, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7/15/04 Signature: Tia Zimmerman (Tia B. Zimmerman)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Deborah A. RATHJEN et al.

Serial No.: 10/702,681

Filing Date: November 5, 2003

For: TUMOUR NECROSIS FACTOR BINDING LIGANDS

Examiner: C. Chan

Group Art Unit: 1644

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the co-pending related U.S. Patent Application No. 10/265,451, filed October 3, 2002. The present application is a continuation of U.S. Patent Appliction No. 10/453,176, filed June 6, 2003, which is a continuation of U.S. Patent Application No. 10/359,934, filed February 7, 2003, which is a continuation of U.S. Patent Application No. 10/327,541, filed

December 20, 2002, which is a continuation of U.S. Patent Application No. 10/265,451, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). If the Examiner requires additional copies of the documents, Applicants will be happy to provide them upon request. The Examiner is requested to make these documents of record in the application.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of __ is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 273402602309. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 15, 2004

Respectfully submitted,

By: _____

Kimberly A. Bolin
Registration No. 44,546

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5740
Facsimile: (650) 494-0792

Form PTO-1449

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 273402602309	Application Number 10/702,681
Applicant: Deborah A. RATHJEN et al.	
Filing Date November 5, 2003	Group Art Unit 1644
Mailing Date July 15, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	09/13/2001	2001/0021513	Puijk et al.			
	2.	03/13/2003	2003/0049256	Tobinick			
	3.	12/11/2003	2003/0228605	Slootstra et al.			
	4.	03/28/1989	4,816,567	Cabilly et al.			
	5.	09/05/1989	4,863,727	Zimmerman et al.			
	6.	06/29/1993	5,223,395	Gero			
	7.	08/30/1994	5,342,613	Creaven et al.			
	8.	07/25/1995	5,436,154	Barbanti et al.			
	9.	04/09/1996	5,506,265	Blitstein-Willinger			
	10.	02/25/1997	5,605,690	Jacobs et al.			
	11.	08/05/1997	5,654,407	Boyle et al.			
	12.	08/19/1997	5,658,570	Newman et al.			
	13.	12/23/1997	5,700,788	Mongelli et al.			
	14.	03/24/1998	5,730,975	Hotamisligil et al.			
	15.	04/21/1998	5,741,488	Feldman et al.			
	16.	05/12/1998	5,750,105	Newman et al.			
	17.	07/07/1998	5,776,947	Kroemer et al.			
	18.	03/30/1999	5,888,511	Skurkovich et al.			
	19.	09/28/1999	5,958,413	Anagnostopulos et al.			
	20.	11/30/1999	5,993,833	DeLacharriere et al.			
	21.	11/30/1999	5,994,510	Adair et al.			
	22.	01/18/2000	6,015,558	Hotamisligil et al.			
	23.	01/09/2001	6,172,202	Marcucci et al.			
	24.	02/20/2001	6,190,691	Mak			
	25.	02/27/2001	6,194,451	Alpegiani et al.			
	26.	07/16/2002	6,419,944	Tobinik			

EXAMINER: | DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 273402602309	Application Number 10/702,681
Applicant: Deborah A. RATHJEN et al.	
Filing Date November 5, 2003	Group Art Unit 1644
Mailing Date July 15, 2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	Translation NO
	27.	04/28/1983	AU 89902/82	Australia				
	28.	02/19/1987	AU 61511/86	Australia				
	29.	09/21/1989	AU 31252/89	Australia				
	30.	05/30/1991	AU 72626/91	Australia				
	31.	07/12/1989	EP 0 323 806	Europe				
	32.	10/30/1991	EP 0 453 898	Europe			Abstract	
	33.	11/11/1992	EP 0 512 528	Europe				
	34.	02/10/1993	EP 0 526 905	Europe				
	35.	03/09/1994	EP 0 585 705	Europe				
	36.	09/14/1994	EP 0 614 984	Europe				
	37.	07/26/1995	EP 0 663 836	Europe				
	38.	04/17/1996	EP 0 706 795	Europe				
	39.	09/02/1998	EP 0 861 850	Europe				
	40.	09/30/1998	EP 0 867 509	Europe				
	41.	10/07/1998	EP 0 869 179	Europe				
	42.	10/14/1998	EP 0 870 827	Europe				
	43.	03/07/1986	JP 61-047500	Japan			Abstract	
	44.	09/10/1990	JP 02-227095	Japan			Abstract	
	45.	06/18/1987	WO 87/03489	WIPO				
	46.	04/21/1988	WO 88/02632	WIPO				
	47.	09/21/1989	WO 89/08460	WIPO				
	48.	10/19/1989	WO 89/09610	WIPO				
	49.	01/25/1990	WO 90/00400	WIPO				
	50.	02/08/1990	WO 90/00902	WIPO				
	51.	03/08/1990	WO 90/01950	WIPO				
	52.	06/14/1990	WO 90/06514	WIPO				

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number 273402602309	Application Number 10/702,681
	Applicant: Deborah A. RATHJEN et al.	
	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	53.	04/04/1991	WO 91/04054	WIPO				
	54.	01/23/1992	WO 92/01059	WIPO				
	55.	02/06/1992	WO 92/01472	WIPO				
	56.	02/20/1992	WO 92/02190	WIPO				
	57.	04/30/1992	WO 92/07076	WIPO				
	58.	07/09/1992	WO 92/11383	WIPO				
	59.	08/06/1992	WO 92/13095	WIPO				
	60.	10/01/1992	WO 92/16553	WIPO				
	61.	02/04/1993	WO 93/02108	WIPO				
	62.	06/10/1993	WO 93/11236	WIPO				
	63.	04/28/1994	WO 94/08609	WIPO				
	64.	04/28/1994	WO 94/08619	WIPO				
	65.	11/19/1998	WO 98/51344	WIPO				
	66.	10/26/2000	WO 00/62790	WIPO				

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	67.	Aderka, D. (1991). "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," *Isr. J. Med. Sci.* 27:52-60.
	68.	Aderka, D. et al. (1989). "IL-6 Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," *J. Immunol.* 143(11):3517-3523.
	69.	Aderka, D. et al. (1992). "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," *Israel J. Med. Sci.*, 28:126-130.
	70.	Aggarwal, B.B. et al. eds. (1992). Tumor Necrosis Factors: Structure, Function, and Mechanism of Action Marcel Dekker, Inc. NY pp. ix -xi. (Table of Contents Only.)
	71.	Alberts, B. et al. (1983). "How Cells Are Studied" Chapter 4 *In* Molecular Biology of the Cell Garland Publishing, Inc. pp. 182-183.
	72.	Amit, A.G. et al. (1986). "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution," *Science* 233(4765):747-753.
	73.	Anonymous (1997). "New Monoclonal Antibody Effective Treatment for Crohn's Disease Therapy," *Doctor's Guide* located at <http://www.main.pslgroup.com> last visited January 20, 2003, three pages.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number 273402602309	Application Number 10/702,681
	Applicant: Deborah A. RATHJEN et al.	
	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	74.	Arnason, B. (1999). "TNF Neutralization in MS: Results of a Randomized, Placebo-Controlled Multicenter Study," *Neurology* 53:457-465.
	75.	Barbanti, E. et al. (1991). "A High-Affinity Neutralizing Anti-Human TNF-Alpha Monoclonal Antibody That Cross-Reacts with Human TNF-Beta," *2nd International Congress on the Immune Consequences of Trauma, Shock and Sepsis Mechanisms and Therapeutic Approaches* Munich Germany (March 6-9, 1991) Abstract No. OR 37, one page.
	76.	Barbuto, J.A.M. et al. (1993). "Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes," *Proceedings of the 84th Annual Meeting of theAmerican Association For Cancer Research* (May 19 - 22, 1993) Orlando, FL. 34:487 Abstract 2904.
	77.	Bard, F. et al. (2000). "Peripherally Administered Antibodies Against Amyloid B-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease," *Nature Medicine* 6(8):916-919.
	78.	Bazzoni, F. et al. (1996). "Seminars in Medicine of the Beth Isreal Hospital; Boston: The Tumor Necrosis Factor Ligand and Receptor Families," New England Journal of Medicine Flier, J.S. et al. eds. 334(26):1717-1725.
	79.	Beck, J. et al. (1987). "Increased Production of TNF-α in Multiple Sclerosis," Abstract D.2., *Immunobiology* 175(1/2):91-92.
	80.	Beck, J. et al. (1988)."Increased Production of Interferon Gamma and Tumor Necrosis Factor Precedes Clinical Manifestation in Multiple Sclerosis: Do Cytokines Trigger Off Exacerbations," *Acta. Neurol. Scand.* 78:318-323.
	81.	Bendtzen, K. et al. (1989). "Native Inhibitors (Autoantibodies) of IL-1α and TNF," *Immunolgy Today* 10(7):222.
	82.	Bendtzen, K. et al. (1990). "Auto-Antibodies to IL-1α and TNFα In Normal Individuals and In Infectious and Immunoinflammatory Disorders," *In* The Physiological and Pathological Effects of Cytokines Wiley-Liss, Inc. 10B:447-452.
	83.	Beutler, B. et al. (1986). "Cachectin and Tumour Necrosis Factor as Two Sides of the Same Biological Coin," *Nature* 320:584-588.
	84.	Blundell, T. et al. (1988). "Knowledge-Based Protein Modelling and Design," Eur. J. Biochem. 172:513-520. (K. Bolin email)
	85.	Borras, E. et al. (2002). "Findings on T Cell Specificity Revealed by Synthetic Combinatorial Libraries," *Journal of Immunological Methods* 267:79-97.
	86.	Borrebaeck, C.A.K. ed. (1995). Antibody Engineering Second Edition, Oxford University Press, p:291.
	87.	Boyle, P. et al. (1993). "A Novel Monoclonal Human IgM Autoantibody Which Binds Recombinant Human and Mouse Tumor Necrosis Factor-α," *Cellular Immunology* 152:556-568.
	88.	Boyle, P. et al. (1993). "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFα on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," *Cellular Immunology* 152:569-581.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number 273402602309	Application Number 10/702,681
	Applicant: Deborah A. RATHJEN et al.	
	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	89.	Braden, B. C. et al. (1995). "Structural Features of the Reactions Between Antibodies and Protein Antigens," *FASEB J.* 9:9-16.
	90.	Braden, B.C. et al. (1998). "Anatomy of an Antibody Molecule: Structure, Kinetics, Thermodynamics and Mutational Studies of the Antilysozyme Antibody D1.3," *Immunol Rev.* 163:45-57.
	91.	Brockhaus, M. et al. (1990). "Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies," *Proc. Nato. Acad. Sci. USA* 87:3127-3131.
	92.	Brok, H.P.M. et al. (2002). "Prevention of Experimental Autoimmune Encephalomyelitis in Common Marmosets Using an Anti-IL-12p40 Monoclonal Antibody," *J. Immunol.* 6554-6563.
	93.	Bruggemann, M. et al. (1989). "The Immunocenicity of Chimeric Antibodies," *J. Exp. Med.* 170:2153-2157.
	94.	Chaudhari, U. et al. (2001). "Efficacy and Safety of Infliximab Monotherapy for Plaque-Type Psoriasis: A Randomised Trial," *Lancet* 357:1842-1847.
	95.	Clark, W.R. (1991). "Types of Antibody Reactions," *In* The Experimental Foundations of Modern Immunolgy, Fourth Edition, John Wiley & Sons, Inc.: New York, NY pp. 143-155.
	96.	Colman, P. M. (1991). "Antigen-Antigen Receptor Interactions," *Curr. Opin. Struct. Biol.* 1:232-236.
	97.	Colman, P.M. (1988). "Structure of Antibody-Antigen Complexes: Implications for Immune Recognition," *Adv Immunol.* 43:99-132.
	98.	Colman, P.M. et al. (1987). "Three-Dimensional Structure of a Complex of Antibody with Influenza Virus Neuraminidase," *Nature* 326:358-363.
	99.	Creasey, A.A. et al. (1987). "Biological Effects of Recombinant Human Tumor Necrosis Factor and Its Novel Muteins on Tumor and Normal Cell Lines," *Cancer Res.* 47:145-149.
	100.	Creaven, P.J. et al. (1991). "Response to Tumor Necrosis Factor in Two Cases of Psoriasis," *J. of the Am. Acad. Dermatol.* 24:735-737.
	101.	Dall'Acqua, W. et al. (1998). "A Mutational Analysis of Binding Interactions in an Antigen - Antibody Protein-Protein Complex," *Biochemistry* 37:7981-7991.
	102.	Davenport, C. et al. (1992). "Stimulation of Human B Cells Specific For *Candida Albicans* For Monoclonal Antibody Production," *FEMS Microbiol. Immunol.* 86:335-343.
	103.	Davies, D. R. et al. (1993). "Antibody Structure," *Acc. Chem. Res.* 26:421-427.
	104.	Davies, D.R. et al. (1990). "Antibody-Antigen Complexes," *Annu Rev Biochem.* 59:439-473.
	105.	Davies, S.J. et al. (2004). "Involvement of TNF in Limiting Liver Pathology and Promoting Parasite Survival During Schistosome Infection," *International Journal for Parasitology* 34:27-36.
	106.	Duncombe, A.S. et al. (1989). "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," *J. Immunol.* 3828-3834.
	107.	Eck, M.J. et al. (1992). "The Structure of Human Lymphotoxin (Tumor Necrosis Factor-β) at 1.9- Å Resolution," *The Journal of Biological Chemistry* 267(4):2119-2122.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Deborah A. RATHJEN et al.	
(Use several sheets if necessary)	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	108.	Eck, S.L. et al. (1996). "Gene-Based Therapy" Chapter 5 *In* The Pharmacological Basis of Therapeutics Goodman and Gilman eds. Ninth Edition, The McGraw Hill Companies pp 77-101.
	109.	Ede, N.J. (2002). "Multiple Parallel Synthesis of Peptides on SynPhase Grafted Supports," *Journal of Immunological Methods* 267:3-11.
	110.	Edmundson, A. B. et al. (2001). "Binding of Synthetic Peptides by a Human Monoclonal IgM with an Unusual Combining Site Structure," *Journal of Molecular Recognition* 14:229-238.
	111.	Elliott, M.J. et al. (1993). "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α," *Arthritis & Rheumatism* 36(12):1681-1690.
	112.	Exley, A.R. et al. (1989). "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," Abstract 184, *Clinical Science* 76(S20):50.
	113.	Fauci, A.S. et al. ed. (1998). Harrison's Priniciples of Internal Medicine 14th Edition, McGraw Hill Companies, Inc., pg. 300.
	114.	Ferrieres, G. et al. (1998). "Human Cardiac Troponin 1: Precise Identification of Antigenic Epitopes and Prediction of Secondary Structure," *Clinical Chemistry* 44(3):487-493.
	115.	Fiers, W. (1999). "Review: Tumor Necrosis Factor: Characterization at the Molecular, Cellular and in vivo Level," *FEBS Lett.* 285(2):199-212.
	116.	Folks, T.M. et al. (1989). "Tumor Necrosis Factor α Induces Expression of Human Immunodeficiency Virus in a Chronically Infected T-Cell Clone," *Proc. Natl. Acad. Sci. USA* 86:2365-2358.
	117.	Fong, Y. et al. (1990). "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," *Clin. Immunol. Immunopathol.* 55:157-170.
	118.	Frank, R. (2002)." The SPOT-Synthesis Technique Synthetic Peptide Arrays on Membrane Supports - Prinicples and Applications," *Journal of Immunological Methods* 267:13-26.
	119.	Garnier, J. et al. (1978). "Analysis of the Accuracy and Implications of Simple Methods for Predicting the Secondary Structure of Globular Proteins," *J. Mol. Biol.* 120:97-120.
	120.	GenBank Accession No. M32046 "Mouse Antibody Response to Group A Strptococcal Carbohydrate," created on April 27, 1993, located at <http://www.ncbi.nlm.nih.gov> last visited on May 6, 2004.
	121.	GenBank Accession No. N90300 "The WashU-Merck EST Project," created on April 2, 1996, located at, located at <http://www.ncbi.nlm.nih.gov> last visited on May 6, 2004.
	122.	Geysen, H. M. et al. (1986). "*A Priori* Delineation of a Peptide Which Mimics a Discontinuous Antigenic Determinant," *Molecular Immunology* 23(7):709-715.
	123.	Geysen, H. M. et al. (1988). "Cognitive Features of Continuous Antigenic Determinants," *Journal of Molecular Recognition* 1(1):32-41.
	124.	Geysen, H.M. (1990). "Molecular Technology: Peptide Epitope Mapping and the Pin Technology," *Southeast Asian J. Trop. Med. Public Health* 21:523-533.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Deborah A. RATHJEN et al.	
(Use several sheets if necessary)	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	125.	Geysen, H.M. et al. (1993). "Screening Chemically Synthesized Peptide Libraries for Biologically-Relevant Molecules," *Bioorganic & Medicinal Chemistry Letters* 3:397-404.
	126.	Gillies, S.D. et al. (1989). "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," *J. Immunol. Methods.* 125:191-202.
	127.	Goh, C. (1990). "Tumour Necrosis Factors in Clinical Practice," *Annals of the Academy of Medicine* 19(2):235-239.
	128.	Gomme, P.T. et al. (1999). "Evaluation of a Pepscan Approach to Identify Epitopes Recognised by Anti-h TSH Monoclonal Antibodies," *J. Biochem. Biophys. Methods* 38:53-70.
	129.	Gorman, S.D. et al. (1990). "Humanisation of Monoclonal Antibodies for Therapy," *Sem. Immunol.* 2:457-466.
	130.	Granier, C. ed. (2002). "Special Issue on 'Methods of Parallel Peptide Synthesis and Their Contributions to Deciphering Molecular Interactions in the Immune System'," *Journal of Immunological Methods* 267:1-2.
	131.	Gray, P.W. et al. (1984). "Cloning and Expression of cDNA for Human Lymphotoxin, a Lymphokine with Tumour Necrosis Activity," *Nature* 312(20/27):721-724.
	132.	Hahn, T. et al. (1985). "Use of Monoclonal Antibodies to a Human Cytotoxin For Its Isolation and For Examining the Self-Induction of Resistance to This Protein," *Proc. Natl. Acad. Sci. USA* 82:3814-3818.
	133.	Harris, W.J. et al. (1993). "Therapeutic Antibodies - The Coming of Age," *TIBTECH* 11:42-44.
	134.	Hayashi, H. et al. (1985). "An Enzyme-Linked Immunosorbent Assay For Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," *Recent Adv. Chemother.* 820-821.
	135.	Herve, P. et al. (1990). "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, *Lymphoma Res.* 9: 591.
	136.	Hird, V. et al. (1990). "Immunotherapy with Monoclonal Antibodies," Chapter 17 *In* Genes and Cancer Carney, D. et al eds. John Wiley & Sons pp. 183-189.
	137.	Ivanyi, J. (1982). "Study of Antigenic Structure and Inhibition of Activity of Human Growth Hormone and Chorionic Somatotropin by Monoclonal Antibodies," *Molecular Immunology* 19(12):1611-1618.
	138.	Jacob, C.O. et al. (1988). "Tumour Necrosis Factor-α in Murine Autoimmune 'Lupus' Nephritis," *Nature* 331:356-358.
	139.	James, K. et al. (1987). "Human Monoclonal Antibody Production: Current Status and Future Prospects," *Journal of Immunological Methods* 100:5-40.
	140.	Jarvis, C.D. et al. (1989). "Mouse Antibody Response to Group a Streptococcal Carbohydrate," *J. Immunology* 143(12):4213-4220.
	141.	Kameyama, K-Z. et al. (1989). "Convenient Plasmid Vectors for Construction of Chimeric Mouse/Human Antibodies," *FEBS Lett.* 244(2):301-306.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number 273402602309	Application Number 10/702,681
	Applicant Deborah A. RATHJEN et al.	
	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	142.	Kassiotis, G. et al. (2001). "Uncoupling the Proinflammatory From the Immunosuppressive Properties of Tumor Necrosis Factor (TNF) at the p55 TNF Receptor Level: Implications For Phathogenesis and Therapy of Autoimmune Demyelination," *J. Exp. Med.* 193(4):427-434.
	143.	Lassalle, P. et al. (1991). "Potential Implication of Endothelial Cells in Bronchial Asthma," *Int. Arch Allergy Appl. Immunol.* 94:233-238.
	144.	Laune, D. et al. (1997). "Systematic Exploration of the Antigen Binding Activity of Synthetic Peptides Isolated From the Variable Regions of Immunoglobulins," *The Journal of Biological Chemistry* 272(49):30937-30944.
	145.	Laune, D. et al. (2002)."Application of the Spot Method to the Identification of Peptides and Amino Acids from the Antibody Paratope That Contribute to Antigen Binding," *Journal of Immunological Methods* 267:53-70.
	146.	Lo Conte, L. et al. (1999). "The Atomic Structure of Protein-Protein Recognition Sites," *J Mol Biol.* 285:2177-2198.
	147.	Luettig, B. et al. (1989). "Evidence For The Existence of Two Forms of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," *The Journal of Immunology* 143(12):4034-4038.
	148.	Mariuzza, R. A. et al. (1993). "The Basics of Binding: Mechanisms of Antigen Recognition and Mimicry by Antibodies," *Curr. Opin. Immunol.* 5:50-55. (Reply Brief - Appendix C5)
	149.	Mateo, C. et al. (2000). "Removal of Amphipathic Epitopes From Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity," *Hybridoma* 19(6):463-471.
	150.	Mease, P.J. (2000). "Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial," *Lancet* 356:385-390.
	151.	Mulé, J.J. et al. (1990). "Antitumor Activity of Recombinant Interleukin 6 in Mice," *The Journal of Experimental Medicine* 171:629-636.
	152.	Nedwin, G.E. et al. (1985). "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," *Nucleic Acids Research* 13(17):6361-6373.
	153.	Oh, C.J. et al. (2000). "Treatment with Anti-Tumor Necrosis Factor-α (TNF-α) Monoclonal Antibody Dramatically Decreases the Clinical Activity of Psoriasis Lesions," *J. of the Am. Acad. Dermatol.* 42:829-830.
	154.	Oliff, A. et al. (1987). "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," *Cell* 50:555-563.
	155.	Omulecki, A. et al. (1996). "Is Pentoxifylline Effective in the Treatment of Psoriasis," *J. of the Am. Acad. Dermatol.* 34(4):714-715.
	156.	Orkin, S.H. et al. (1995). "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," *NIH* 29 pages.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Deborah A. RATHJEN et al.	
(Use several sheets if necessary)	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	157.	Osband, M.E. et al. (1990). "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy," *Immunol. Today* 11(6):193-195.
	158.	Padlan, E. A. (1996). "X-Ray Crystallography of Antibodies" *In* Advances in Protein Chemistry Richards, F.M. et al. eds., Academic Press 49:57-133.
	159.	Padlan, E.A. et al. (1989). "Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL-10 Fab-lysozyme Complex," *Proc Natl Acad Sci USA* 86(15):5938-5942.
	160.	Pardridge, W.M. (1994). "New Approaches to Drug Delivery Through the Blood-Brain Barrier," Abstract, *Trends in Biotechnology* 12:239-245.
	161.	Parrillo, J. E. (1993). "Pathogenetic Mechanisms of Septic Shock," *NE journal of Medicine,* 328(20):1471-1477.
	162.	Partsch, G. et al. (1998). "Upregulation of Cytokine Receptors sTNF-R55, sTNF-R75, and sIL-2R in Psoriatic Arthritis Synovial Fluid," *J. Rheumatol.* 25:105-110.
	163.	Paul, W.E. ed. (1993). "Immunoglobulins: Structure and Function" Chapter 9 *In* Fundamental Immunology, Third Edition, Raven Press Ltd. New York pp: 292-293.
	164.	Paulus, H. (1985). "Preparation and Biomedical Applications of Bispecific Antibodies," *Behring Inst. Mitt.* 78:118-132.
	165.	Pennington, J. (1992). "TNF: Therapeutic Target in Patients with Sepsis," *ASM News*, 58(9): 479-482.
	166.	Petersen, C.M. et al. (1989). "Bioactive Human Recombinant Tumor Necrosis Factor-α: An Unstable Dimer?" *Eur. J. Immunol.* 19:1887-1894.
	167.	Poljak, R.J. (1991). "Structure of Antibodies and Their Complexes with Antigens," *Mol Immunol.* 28(12):1341-1345.
	168.	Potter, R. (1993). "Enzon Lines Up 11 New Alliances in a Busy Year," *Biotechnology* 11:432-433.
	169.	Radford, A.J. et al. (1990). "Epitope Mapping of the *Mycobacterium bovis* Secretory Protein MPB70 Using Overlapping Peptide Analysis," *J. Gen. Microbiol.* 136:265-272.
	170.	Reed, C et al. (1997). "Crystal Structure of TNF-Alpha Mutant R31D with Greater Affinity for Receptor R1 Compared with R2," *Protein Eng.* 10(10):1101-1107.
	171.	Reineke, U. (2004)."Antibody Epitope Mapping Using Arrays of Synthetic Peptides" Chapter 26 *In* Methods in Molecular Biology: Antibody Engineering - Methods and Protocols Lo, B.K.C. ed. Humana Press, Inc.: Totowa, NJ, Vol. 248 pp. 443-463.
	172.	Reineke, U. et al. (1999). "Antigen Sequence- and Library-Based Mapping of Linear and Discontinuous Protein-Protein-Interaction Sites by Spot Synthesis," *Current Topics in Microbiology and Immunology* 243:23-36.
	173.	Reineke, U. et al. (2001). "Applications of Peptide Arrays Prepared by the SPOT-Technology," *Current Opinion in Biotechnology* 12:59-64.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant: Deborah A. RATHJEN et al.	
(Use several sheets if necessary)	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	174.	Rhein, R. (October 4, 1993). "Another Sepsis Drug Down-Immunex' TNF Receptor," *Biotechnology Newswatch*, two pages.
	175.	Rodda, S.J. (2002). "Peptide Libraries for T Cell Epitope Screening and Characterization," *Journal of Immunological Methods* 267:71-77.
	176.	Sagawa, Y. et al. (1993)."Is Sustained Production of Tumor Necrosis Factor-α Relevant to the Development of Pustular Psoriasis?" *Dermatology* 187:81-83.
	177.	Sayle, R.A. et al. (1995). "RasMol: Biomolecular Graphics For All," *Trends in Biochemical Science* (TIBS) 20(9):374-376.
	178.	Schwenger, P. et al. (1996). "Inhibition of Tumor Necrosis Factor-Induced p42/p44 Mitogen Activated Protein Kinase Activation by Sodium Salicylate," *The Journal of Biological Chemistry* 271(14):8089-8094.
	179.	Seckinger, P. et al. (1989). "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor α Inhibitor," *The Journal of Biological Chemistry* 264(20):11966-11973.
	180.	Selmaj, K. et al. (1987). "Tumor Necrosis Factor Mediates Myelin Damage in Organotypic Cultures of Nervous Tissue," Abstract, *Journal of Neuroimmunology* 16(1):159.
	181.	Selmaj, K. et al. (1991). "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination," *Ann. Neurol.* 30:694-700.
	182.	Sheriff, S. et al. (1987). "Three-Dimensional Structure of an Antibody-Antigen Complex," *Proc Natl Acad Sci U S A.* 84(22):8075-8079.
	183.	Siegel, S.A. et al. (1995). "The Mouse/Human Chimeric Monoclonal Antibody cA2 Neutralizes TNF in Vitro and Protects Transgenic Mice from Cachexia and TNF Lethality in Vivo," *Cytokine* 7(1):15-25.
	184.	Simpson, S.Q. et al. (1989). "Role of Tumor Necrosis Factor in Sepsis and Acute Lung Injury," *Critical Care Clinics* 5(1):27-47.
	185.	Starnes, H.F. Jr. et al. (1990). "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal *Escherichia coli* Infection and Lethal Tumor Necrosis Factor-α Challenge in Mice," *J. Immunol.* 145(12):4185-4191.
	186.	Sunahara, N. et al. (1988). "Simple Enzyme Immunoassay Methods for Recombinant Human Tumor Necrosis Factor α and its Antibodies Using A Bacterial Cell Wall Carrier," *J. Immol. Methods* 109:203-214.
	187.	Tainer, J.A. et al. (1991). "Defining Antibody-Antigen Recognition: Towards Engineered Antibodies and Epitopes," *Int. Rev. Immunol.* 7:165-188.
	188.	Targan, S.R. et al. (1997). "A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α For Crohn's Disease," *New England Journal of Medicine* 337(15):1029-1035.
	189.	Trentham, D.E. (1991). "Immunotherapy and Other Novel Therapies," *Current Opinion in Rheumatology* 3:369-372.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number 273402602309	Application Number 10/702,681
	Applicant: Deborah A. RATHJEN et al.	
	Filing Date November 5, 2003	Group Art Unit 1644
	Mailing Date July 15, 2004	

	190.	Tribbick, G. (2002). "Multipin Peptide Libraries for Antibody and Receptor Epitope Screening and Characterization," *Journal of Immunological Methods* 267:27-35.
	191.	Underwood, J.R. et al. (1994). "Monoclonal Anti-H1 Histone Autoantibodies From Unimmunized Balb/c Mice. Specificity and V_H and V_L Domain Sequences," *Journal of Autoimmunity* 7:291-320.
	192.	Van Oosten, B.W. et al. (1996). "Increased MRI Activity and Immune Activation in Two Multiple Sclerosis Patients Treated with the Monoclonal Anti-Tumor Necrosis Factor Antibody cA2," *Neurology* 47:1531-1534.
	193.	Van Oosten, B.W. et al. (1997). "Treatment of Multiple Sclerosis with the Monoclonal Anti-CD4 An tibody cM-T412: Results of a Randomized, Double-Blind, Placebo-Controlled, MR-Monitored Phase II Trial," Abstract, *Neurology* 49(2):351-357.
	194.	Van Ostade, X. et al. (1991). "Localization of the Active Site of Human Tumour Necrosis Factor (hTNF) by Mutational Analysis," *The EMBO Journal* 10(4):827-836.
	195.	Van Ostade, X. et al. (1993). "Human TNF Mutants With Selective Activity on the p55 Receptor," *Nature* 361:266-269.
	196.	Verhoef, J. et al. (1990). "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," *Eur. J. Clin. Microbiol. Infect. Dis.* 9(4): 247-250.
	197.	Verma, I.M. et al. (1997). "Gene Therapy--Promises, Problems and Prospects," *Nature* 389:239-242.
	198.	Vilcek, J. (1998). "The Cytokines: An Overview" Chapter 1 *In* The Cytokine Handbook Third Edition Academic Press Ltd., pp. 1-20.
	199.	Walker, R.E. (1996.) "Inhibition of Immunoreactive Tumor Necrosis Factor-Alpha by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1," *Journal of Infect. Dis.* 174(1):63-68.
	200.	Ware, C.F. et al. (1998). "Tumor Necrosis Factor-Related Ligands and Receptors" Chapter 20 *In* The Cytokine Handbook Third Edition Academic Press Ltd. pp. 549-592.
	201.	Whittle, N. et al. (1989). "Construction and Expression of a CDR-Grafter Anti-TNF Antibody," Abstract A342, *J. Cell Biochem.* Supl. 13A:96.
	202.	Wilson, I.A. et al. (1993). "Antibody-Antigen Interactions," *Current Opinion in Structural Biology* 3:113-118.
	203.	Yamagishi, J-i. et al. (1990). "Mutational Analysis of Structure - Activity Relationships in Human Tumor Necrosis Factor-Alpha," *Prot. Eng.* 3(8):713-719.
	204.	Yan, L. et al. (1991). "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha," *Chinese J. of Biotechnology* 7(2):121-126.
	205.	Zhang, M. et al. (1998). "Tumor Necrosis Factor" Chapter 19 *In* The Cytokine Handbook Third Edition Academic Press Ltd., pp. 517-547.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.